Business Wire

New Edition of Arthur D. Little’s Innovation Magazine Focuses on Business Resilience

20.9.2022 15:18:00 EEST | Business Wire | Press release

Share

Arthur D. Little (ADL) has published The New Resilience – Innovating From Resources To Customers – the latest edition of its innovation magazine PRISM. This issue focuses on the different ways that businesses can meet the challenges of recent years, from resource management to creative thinking.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220920005785/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Arthur D. Little Prism S2 2022: The New Resilience - Innovating from Resources to Customers (Graphic: Business Wire)

The magazine features seven articles:

Winning The War For Digital Talent
Digital skills are today central to competitiveness, value creation, and business resilience, and therefore simply outsourcing to address the digital skills gap is becoming less attractive. This edition’s lead article outlines some better strategies that businesses can adopt.

Achieving Resilience And Sustainability For The EV Battery Supply Chain
Electric vehicles are at the heart of decarbonising mobility, yet battery supply chains are complex and fragile. This article sets out a toolkit for building a resilient battery value chain based on end-to-end visibility.

Why The Bio-Based Materials Market Is Finally Poised For Growth
Many of the challenges that have held back the increased production of bio-based materials are being overcome. This article looks at how players can identify and successfully harness these new areas for growth.

Disruption – Can Banks Strike Back?
Many believe the traditional universal bank is dead – but transformation is possible. This article identifies the six priorities traditional players need to embrace if they are to have any chance of survival.

Closing The Innovation Gaps Between Business Units
ADL research has found that business units often fail to work consistently and share best practices around innovation. This article outlines the causes of this gap, and how it can be bridged.

Creative Thinking For Leaders
Business leaders face increasing complexity, a faster moving world, and a need to overcome their own cognitive biases. Creative thinking is essential to meet these challenges, but widely misunderstood. This article debunks these myths and provides some practical approaches for leaders to use.

How Insects Can Reinvent The Food Chain
An interview with Antoine Hubert, co-founder of Ÿnsect, a rapidly growing agri-food company set to become one of the global leaders in transforming insects into high-performance natural protein solutions.

Rick Eagar, Partner Emeritus at Arthur D. Little and Chief Editor of PRISM, comments: “Only a few years ago, resilience mainly focused on how to manage operational risks and respond effectively to crises. But today it’s also about innovation along the entire value chain, from resources to customers, and finding new, more agile ways of doing business in a world where disruption is the norm. This latest edition of PRISM is a guide to resilience in all its forms.”

This latest edition of PRISM can be viewed here: https://tinyurl.com/5n7t68mr

About Arthur D. Little
Arthur D. Little has been at the forefront of innovation since 1886. We are an acknowledged thought leader in linking strategy, innovation and transformation in technology-intensive and converging industries. We navigate our clients through changing business ecosystems to uncover new growth opportunities. We enable our clients to build innovation capabilities and transform their organizations.

Our consultants have strong practical industry experience combined with excellent knowledge of key trends and dynamics. ADL is present in the most important business centers around the world. We are proud to serve most of the Fortune 1000 companies, in addition to other leading firms and public sector organizations.

For further information, please visit www.adlittle.com or www.adl.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Cate Bonthuys
Catalyst Comms
+44 7746 546773
cate@catalystcomms.co.uk

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye